Adage Capital Partners Gp, L.L.C. Eye Point Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 6,800,000 shares of EYPT stock, worth $73.1 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
6,800,000
Previous 6,200,000
9.68%
Holding current value
$73.1 Million
Previous $33.6 Million
90.42%
% of portfolio
0.11%
Previous 0.07%
Shares
13 transactions
Others Institutions Holding EYPT
# of Institutions
159Shares Held
67.1MCall Options Held
214KPut Options Held
994K-
Cormorant Asset Management, LP Boston, MA8.33MShares$89.5 Million7.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$73.1 Million2.2% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.6MShares$49.4 Million0.09% of portfolio
-
Franklin Resources Inc San Mateo, CA4.3MShares$46.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$40.9 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $366M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...